LAYANAN INI TIDAK TERSEDIA DI WILAYAH ANDA

6 4 G LTD

Britania Raya

Didirikan

2015 (11 Tahun)

Ditemukan

Terakhir online: Tidak ada aktivitas terbaru

Kunjungi Situs Web

TrustScore tidak tersediaSkor belum cukup untuk menampilkan tren.

Jadilah yang pertama memberi rating dan ulasan untuk perusahaan ini.

SKOR KESELURUHAN

Lisensi

--/40

Ulasan

--/60

0 ulasan

Disediakan oleh TrustFinance

TrustScore tidak tersediaSkor belum cukup untuk menampilkan tren.

Jadilah yang pertama memberi rating dan ulasan untuk perusahaan ini.

FTD LIMITED

(505 ulasan)

British Virgin Islands

2017

(9 tahun)

Informasi Keamanan :

BVI FSC

Informasi Keamanan

Peringatan

Perusahaan ini saat ini Belum Terbukti.

Harap berhati-hati terhadap potensi risiko!

Lisensi

Lisensi Kelas A

Dikeluarkan oleh regulator terkenal secara global, lisensi ini memastikan perlindungan pedagang tertinggi melalui kepatuhan yang ketat, pemisahan dana, asuransi, dan audit rutin. Penyelesaian sengketa dan kepatuhan terhadap standar AML/CTF semakin meningkatkan keamanan.

Lisensi Kelas B

Diberikan oleh regulator regional yang dihormati, lisensi ini menawarkan langkah-langkah keamanan yang kuat seperti pemisahan dana, pelaporan keuangan, dan skema kompensasi. Meskipun sedikit kurang ketat daripada Tingkat 1, lisensi ini memberikan perlindungan regional yang dapat diandalkan.

Lisensi Kelas C

Dikeluarkan oleh regulator di pasar negara berkembang, lisensi ini menawarkan perlindungan dasar seperti persyaratan modal minimum dan kebijakan AML. Pengawasan kurang ketat, sehingga pedagang harus berhati-hati dan memverifikasi langkah-langkah keamanan.

Lisensi Kelas D

Dari yurisdiksi dengan pengawasan minimal, lisensi ini seringkali tidak memiliki perlindungan utama seperti pemisahan dana dan asuransi. Meskipun menarik untuk fleksibilitas operasional, lisensi ini menimbulkan risiko yang lebih tinggi bagi pedagang.

Informasi Perusahaan

Mengenal 6 4 G LTD

Tampilkan Lebih Banyak

Informasi Perusahaan

Mengenal 6 4 G LTD

6 4 G LTD, operating under the brand name 64FX, is an online trading provider incorporated in St. Vincent & the Grenadines. The company's mission is to offer a transparent and high-quality trading environment for both retail and institutional clients. It provides access to global financial markets, including Forex, indices, commodities, and shares, utilizing the popular MetaTrader 5 trading platform and offering various account types to suit different trading needs.

Tampilkan Lebih Banyak

Industri

Valuta Asing Pialang RitelUTAMA
Keuangan Layanan Lainnya

Perangkat Lunak

Tidak ada data yang tersedia

Sepertinya bagian ini kosong. Segera kembali untuk pembaruan!

Kontak

Sosial

Perusahaan belum memperbarui informasinya.

Ulasan

6 4 G LTD Ulasan

Ulasan

Total 0

Urutkan berdasarkan

Filter

Informasi Perusahaan

Mengenal 6 4 G LTD

Tampilkan Lebih Banyak

Informasi Perusahaan

Mengenal 6 4 G LTD

6 4 G LTD, operating under the brand name 64FX, is an online trading provider incorporated in St. Vincent & the Grenadines. The company's mission is to offer a transparent and high-quality trading environment for both retail and institutional clients. It provides access to global financial markets, including Forex, indices, commodities, and shares, utilizing the popular MetaTrader 5 trading platform and offering various account types to suit different trading needs.

Tampilkan Lebih Banyak

Industri

Valuta Asing Pialang RitelUTAMA
Keuangan Layanan Lainnya

Perangkat Lunak

Tidak ada data yang tersedia

Sepertinya bagian ini kosong. Segera kembali untuk pembaruan!

Kontak

Sosial

Perusahaan belum memperbarui informasinya.

Berita

TrustFinance Badan Intelijen

Tanggal penelitian: Mei 14, 2026

The website provides comprehensive resources and tools related to personal finance, including credit cards, banking, loans, insurance, investing, small business, and taxes. Users can compare various financial products, access calculators, and read guides to help make informed financial decisions. The site emphasizes independent and objective information while also featuring partner compensation disclosures.

The website provides comprehensive resources and tools related to personal finance, including credit cards, banking, loans, insurance, investing, small business, and taxes. Users can compare various financial products, access calculators, and read guides to help make informed financial decisions. The site emphasizes independent and objective information while also featuring partner compensation disclosures.

The article discusses GeneAgent, an AI tool designed for gene-set analysis that utilizes large language models (LLMs) to autonomously verify its outputs through interactions with biological databases. It aims to reduce inaccuracies, referred to as 'hallucinations', commonly associated with LLMs. GeneAgent has been evaluated against existing models, showing superior accuracy in generating functional descriptions for gene sets. The study highlights the importance of self-verification in enhancing the reliability of gene function annotations, showcasing GeneAgent's ability to produce informative insights from gene sets derived from various sources, including mouse melanoma cell lines.

The article discusses GeneAgent, an AI tool designed for gene-set analysis that utilizes large language models (LLMs) to autonomously verify its outputs through interactions with biological databases. It aims to reduce inaccuracies, referred to as 'hallucinations', commonly associated with LLMs. GeneAgent has been evaluated against existing models, showing superior accuracy in generating functional descriptions for gene sets. The study highlights the importance of self-verification in enhancing the reliability of gene function annotations, showcasing GeneAgent's ability to produce informative insights from gene sets derived from various sources, including mouse melanoma cell lines.

The article presents the development and validation of an autonomous artificial intelligence (AI) agent designed to assist in clinical decision-making for oncology. This AI agent integrates multimodal data and utilizes advanced tools, including GPT-4, to support personalized treatment strategies. It was evaluated using 20 realistic patient cases, achieving high accuracy in clinical conclusions and effectively citing relevant oncology guidelines. The study illustrates how combining language models with precision oncology tools can enhance decision-making accuracy, paving the way for AI-driven personalized oncology support systems.

The article presents the development and validation of an autonomous artificial intelligence (AI) agent designed to assist in clinical decision-making for oncology. This AI agent integrates multimodal data and utilizes advanced tools, including GPT-4, to support personalized treatment strategies. It was evaluated using 20 realistic patient cases, achieving high accuracy in clinical conclusions and effectively citing relevant oncology guidelines. The study illustrates how combining language models with precision oncology tools can enhance decision-making accuracy, paving the way for AI-driven personalized oncology support systems.

Medicare Supplement Plan G is a high-coverage insurance plan for new Medicare members, covering most out-of-pocket costs not included in Original Medicare, such as copayments and deductibles. It offers comprehensive coverage, including excess charge coverage, but comes with higher premiums. The plan is standardized, meaning all providers offer the same benefits regardless of price. While it does not cover the Part B deductible, it is often considered a valuable option for those willing to pay more for extensive benefits. The best time to enroll is during the six-month open enrollment period starting at age 65 and enrolled in Medicare Part B.

Medicare Supplement Plan G is a high-coverage insurance plan for new Medicare members, covering most out-of-pocket costs not included in Original Medicare, such as copayments and deductibles. It offers comprehensive coverage, including excess charge coverage, but comes with higher premiums. The plan is standardized, meaning all providers offer the same benefits regardless of price. While it does not cover the Part B deductible, it is often considered a valuable option for those willing to pay more for extensive benefits. The best time to enroll is during the six-month open enrollment period starting at age 65 and enrolled in Medicare Part B.

The study investigates zilebesiran, an RNA interference therapeutic agent targeting angiotensinogen, for managing hypertension. In a phase 1 trial, 107 patients received varying doses of zilebesiran or placebo. Results showed significant dose-dependent reductions in serum angiotensinogen levels and sustained decreases in systolic and diastolic blood pressure for up to 24 weeks. Mild injection-site reactions were noted, with no serious adverse events related to hypotension or renal function. The findings support further evaluation of zilebesiran as a potential treatment for hypertension.

The study investigates zilebesiran, an RNA interference therapeutic agent targeting angiotensinogen, for managing hypertension. In a phase 1 trial, 107 patients received varying doses of zilebesiran or placebo. Results showed significant dose-dependent reductions in serum angiotensinogen levels and sustained decreases in systolic and diastolic blood pressure for up to 24 weeks. Mild injection-site reactions were noted, with no serious adverse events related to hypotension or renal function. The findings support further evaluation of zilebesiran as a potential treatment for hypertension.

Disediakan oleh Analisis AI TrustFinance

Berita

TrustFinance Badan Intelijen

Tanggal penelitian: Mei 14, 2026

The website provides comprehensive resources and tools related to personal finance, including credit cards, banking, loans, insurance, investing, small business, and taxes. Users can compare various financial products, access calculators, and read guides to help make informed financial decisions. The site emphasizes independent and objective information while also featuring partner compensation disclosures.

The article discusses GeneAgent, an AI tool designed for gene-set analysis that utilizes large language models (LLMs) to autonomously verify its outputs through interactions with biological databases. It aims to reduce inaccuracies, referred to as 'hallucinations', commonly associated with LLMs. GeneAgent has been evaluated against existing models, showing superior accuracy in generating functional descriptions for gene sets. The study highlights the importance of self-verification in enhancing the reliability of gene function annotations, showcasing GeneAgent's ability to produce informative insights from gene sets derived from various sources, including mouse melanoma cell lines.

The article presents the development and validation of an autonomous artificial intelligence (AI) agent designed to assist in clinical decision-making for oncology. This AI agent integrates multimodal data and utilizes advanced tools, including GPT-4, to support personalized treatment strategies. It was evaluated using 20 realistic patient cases, achieving high accuracy in clinical conclusions and effectively citing relevant oncology guidelines. The study illustrates how combining language models with precision oncology tools can enhance decision-making accuracy, paving the way for AI-driven personalized oncology support systems.

Medicare Supplement Plan G is a high-coverage insurance plan for new Medicare members, covering most out-of-pocket costs not included in Original Medicare, such as copayments and deductibles. It offers comprehensive coverage, including excess charge coverage, but comes with higher premiums. The plan is standardized, meaning all providers offer the same benefits regardless of price. While it does not cover the Part B deductible, it is often considered a valuable option for those willing to pay more for extensive benefits. The best time to enroll is during the six-month open enrollment period starting at age 65 and enrolled in Medicare Part B.

The study investigates zilebesiran, an RNA interference therapeutic agent targeting angiotensinogen, for managing hypertension. In a phase 1 trial, 107 patients received varying doses of zilebesiran or placebo. Results showed significant dose-dependent reductions in serum angiotensinogen levels and sustained decreases in systolic and diastolic blood pressure for up to 24 weeks. Mild injection-site reactions were noted, with no serious adverse events related to hypotension or renal function. The findings support further evaluation of zilebesiran as a potential treatment for hypertension.

Disediakan oleh Analisis AI TrustFinance

6 4 G LTD

FTD LIMITED

Informasi Perusahaan

Informasi Perusahaan